These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35475907)

  • 1. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetes Care; 2022 Jun; 45(6):1391-1399. PubMed ID: 35475907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
    Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
    Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-severe hypoglycemia in type 1 diabetes: a randomized crossover trial comparing two quantities of oral carbohydrates at different insulin-induced hypoglycemia ranges.
    Taleb N; Gingras V; Cheng R; Parent V; Messier V; Bovan D; Shohoudi A; Brazeau AS; Rabasa-Lhoret R
    Front Endocrinol (Lausanne); 2023; 14():1186680. PubMed ID: 37334295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetologia; 2023 Jul; 66(7):1208-1217. PubMed ID: 37037948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
    Pieber TR; Aronson R; Hövelmann U; Willard J; Plum-Mörschel L; Knudsen KM; Bandak B; Tehranchi R
    Diabetes Care; 2021 Jun; 44(6):1361-1367. PubMed ID: 35239971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasiglucagon: an effective medicine for severe hypoglycemia.
    Xu B; Tang G; Chen Z
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1783-1790. PubMed ID: 34223944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Nielsen CK; Øhrstrøm CC; Kielgast UL; Hansen DL; Hartmann B; Holst JJ; Lund A; Vilsbøll T; Knop FK
    Diabetes Care; 2022 Jun; 45(6):1476-1481. PubMed ID: 35320361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
    Bailey TS; Willard J; Klaff LJ; Yager Stone J; Melgaard A; Tehranchi R
    Diabetes Obes Metab; 2021 Oct; 23(10):2329-2335. PubMed ID: 34169625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
    Li S; Hu Y; Tan X; Wang D; Hu J; Zou P; Wang L
    Expert Opin Pharmacother; 2020 Aug; 21(11):1311-1318. PubMed ID: 32267182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children.
    Thornton PS; De Leon DD; Empting S; Zangen D; Kendall DM; Birch S; Bøge E; Ivkovic J; Banerjee I
    J Clin Endocrinol Metab; 2024 Mar; 109(4):1071-1079. PubMed ID: 37930757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
    Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
    Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasiglucagon for treating severe hypoglycemia in patients with diabetes.
    Ju Y; Zhang D; Yang J
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):799-803. PubMed ID: 35848442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis.
    Maji S; Mohanty RR; Maiti R
    Balkan Med J; 2023 Oct; 40(6):400-408. PubMed ID: 37735694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial.
    Cheng R; Taleb N; Wu Z; Bouchard D; Parent V; Lalanne-Mistrih ML; Boudreau V; Messier V; Lacombe MJ; Grou C; Brazeau AS; Rabasa-Lhoret R
    Diabetes Care; 2024 Mar; 47(3):476-482. PubMed ID: 38194601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study.
    Ranjan A; Schmidt S; Damm-Frydenberg C; Steineck I; Clausen TR; Holst JJ; Madsbad S; Nørgaard K
    Diabetes Care; 2017 Jan; 40(1):132-135. PubMed ID: 27797928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
    Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.